Ausência de influência da sÃndrome metabólica na atividade da artrite reumatóide
Absence of metabolic syndrome influence in rheumatoid arthritis activity
Breno Martins Farinazo, Mauro Marcelo Furtado Real Júnior, Cezar Augusto Muniz Caldas
Resumo
Objetivo: Identificar a influência da SÃndrome Metabólica (SM) na resposta ao tratamento dos pacientes portadores de Artrite Reumatoide (AR). Metodologia: Foi realizado um estudo do tipo transversal, descritivo e analÃtico, no perÃodo de setembro de 2013 a junho de 2014. A coleta de dados foi efetuada via protocolo de pesquisa elaborado pelos autores no ambulatório de Reumatologia do Centro de Especialidades Médicas (CEMEC) do Centro Universitário do Estado do Pará (CESUPA). Foram incluÃdos pacientes do sexo feminino, maiores de 18 anos e com diagnóstico de AR. Foram excluÃdos da pesquisa todos os pacientes tabagistas, com associação com outra doença autoimune, nefropatas, hepatopatas, mulheres gestantes, menopausadas e/ou em uso de contraceptivos hormonais. Resultados: Todas as pacientes (27) eram do sexo feminino, com média de idade de 40,89 ± 6,71anos e de tempo de doença de 7,67 ± 6,02anos, sendo que 21 pacientes (77,8%) apresentaram fator reumatóide positivo. Quanto à atividade da doença, a Velocidade de Hemossedimentação (VSH) apresentou média de 35,07 ± 17,43mm/h e a ProteÃna C Reativa (PCR) 13,85 ± 18,6mg/dl, respectivamente. A média do Disease Activity Score de 28 articulações (DAS28) foi de 4,69 ± 1,18. A frequência de SM encontrada entre os pacientes foi de 33,3% (n = 9). Em relação à atividade da doença mensurada pelo DAS28 (4,38 ± 0,74 vs. 4,84 ± 1,34, p = 0,263), VHS (33,44 ± 13,87mm/h vs. 35,94 ± 19,39mm/h, p = 0,709) e PCR (19,33 ± 26,66 mg/dl vs. 11,11 ± 13,07 mg/dl, p = 0,403), não houve diferença estatÃstica entre os grupos com SM e sem SM (p=0,263). Conclusão: o presente estudo constatou que a presença de SM não influenciou na resposta ao tratamento nos pacientes com AR do CEMEC, não guardando relação com a atividade da doença, seja através de exames laboratoriais ou avaliada através do DAS28.
Palavras-chave
Abstract
Purpose: To identify the influence of Metabolic Syndrome (MS) in the response to treatment of patients with Rheumatoid Arthritis (RA). Methods: A cross-sectional, descriptive and analytical study was carried out from September 2013 to June 2014. Data collection was done through a research protocol developed by the authors at the ambulatory of Rheumatology of the Center of Medical Specialties (CEMEC) of the University Center of the State of Pará (CESUPA). We included female patients, older than 18 years and diagnosed with RA. All the smoking patients, with association with another autoimmune disease, nephropathy, hepatopathy, pregnant women, menopausal women and / or hormonal contraceptives were excluded from the study. Results:All the patients (27) were female, with a mean age of 40.89 ± 6.71 years and a disease time of 7.67 ± 6.02 years, with 21 patients (77.8%) presenting positive rheumatoid factor. Regarding the disease activity, the Erythrocyte Sedimentation Rate (ESR) presented a mean of 35.07 ± 17.43 mm / h and the C Rective Protein 13.85 ± 18.6 mg / dl, respectively. The mean Disease Activity Score of 28 joints was 4.69 ± 1.18. The frequency of MS found among patients was 33.3% (n = 9). In relation to the disease activity measured by DAS28 (4.38 ± 0.74 vs. 4.84 ± 1.34, p = 0.263), HSV (33.44 ± 13.87 mm / h vs. 35.94 ± 19, 39mm / h, p = 0.709) and CRP (19.33 ± 26.66 mg / dl vs. 11.11 ± 13.07 mg / dl, p = 0.403), there was no statistical difference between the SM and without MS (p = 0.263). Conclusion: The present study found that the presence of MS did not influence the response to treatment in patients with RA of CEMEC, not either related to disease activity, through laboratory tests or evaluated through the DAS28.
Keywords
Referências
1. Santos MJ, Fonseca JE. Metabolic syndrome, inflammation and atherosclerosis – the role of adipokines in health and in systemic inflammatory rheumatic diseases. Acta Reumatol Port. 2009;34(4):590-8. PMid:20852572.
2. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9(48):48. http://dx.doi. org/10.1186/1741-7015-9-48. PMid:21542944.
3. Pereira IA, Mota LMH, Cruz BA, Brenol CV, Fronza LSR, Bertolo MB, et al. Consenso 2012 da Sociedade Brasileira de Reumatologia sobre o manejo de comorbidades em pacientes com artrite reumatoide. Rev Bras Reumatol. 2012;52(4):483-95. http://dx.doi.org/10.1590/ S0482-50042012000400002.
4. Crowson CS, Myasoedova E, Davis III JM, Matteson EL, Roger VL, Therneau TM, et al. Increased Prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol. 2011;38(1):29-35. http://dx.doi.org/10.3899/ jrheum.100346. PMid:20952464.
5. Cunha VR, Brenol CV, Brenol JC, Fuchs SC, Arlindo EM, Melo IM, et al. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scand J Rheumatol. 2012;41(3):186-91. http://dx.doi.org/10.3109/03009742.2011.6264 43. PMid:22416768.
6. Abella V, Scotece M, Conde J, López V, Lazzaro V, Pino J, et al. Adipokines, metabolic syndrome and rheumatic diseases. J Immunol Res. 2014;2014:343746. http://dx.doi.org/10.1155/2014/343746. PMid:24741591.
7. Giles JT, Allison M, Blumenthal RS, Post W, Gelber AC, Petri M, et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum. 2010;62(11):3173-82. http://dx.doi.org/10.1002/art.27629. PMid:20589684.
8. Ferraz-Amaro I, González-Juanatey C, López-Mejias R, Riancho-Zarrabeitia L, González-Gay MA. Metabolic Syndrome in Rheumatoid Arthritis. Mediators Inflamm. 2013;2013:1-11. http://dx.doi.org/10.1155/2013/710928.
9. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK, Kritikos HD, et al. Metabolic syndrome is common among middleto-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross- sectional, controlled, study. Ann Rheum Dis. 2007;66(1):28-33. http://dx.doi.org/10.1136/ard.2006.053488. PMid:16793841.
10. Zarpellon RSM, Dias MM, Skare TL. Perfil nutricional na artrite reumatoide. Rev Bras Reumatol. 2014;54(1):68-72. http://dx.doi.org/10.1016/j. rbr.2014.01.007. PMid:24878796.
11. Fuentes E, Fuentes F, Vilahur G, Badimon L, Palomo A. Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediators Inflamm. 2013;2013:136584. http://dx.doi.org/10.1155/2013/136584. PMid:23843680.
12. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Metabolic syndrome in rheumatoid arthritis. Maedica (Buchar). 2012;7(2):148-52. PMid:23399930.
13. Hayashi H, Satoi K, Sato-Mito N, Kaburagi T, Yoshino H, Higaki M, et al. Nutritional status in relation to adipokines and oxidative stress is associated with disease activity in patients with rheumatoid arthritis. Nutrition. 2012;28(11-12):1109-14. http://dx.doi.org/10.1016/j. nut.2012.02.009. PMid:23044162.
14. Zhang J, Fu L, Shi J, Chen X, Li Y, Ma B, et al. The risk of metabolic syndrome in patients with rheumatoid arthritis: a meta-analysis of observational studies. PLoS One. 2013;8(10):e78151. http://dx.doi.org/10.1371/journal.pone.0078151. PMid:24205134.
15. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. 2010 rheumaotid arthritis classification criteria: an american college of rheumatology / european league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81. http://dx.doi. org/10.1002/art.27584. PMid:20872595.
16. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(5 Suppl 39):100-8. PMid:16273793.
17. Cortez-Dias N, Martins S, Belo A, Fiuza M, Investigadores do estudo VALSIM. Comparações de diferentes definições de sÃndrome metabólica: implicações no risco de doença coronária e acidente vascular cerebral. Rev Port Cardiol. 2011;30(2):139-69. PMid:21553609.
18. Brown TM, Vaidya D, Rogers W, Waters D, Howard B, Tardif J, et al. Does prevalence of the metabolic syndrome in women with coronary artery disease differ by the ATPIII and IDF criteria? J Womens Health (Larchmt). 2008;17(5):841-7. http://dx.doi.org/10.1089/jwh.2007.0536. PMid:18537485.
19. Vinluan CM, Zreikat HH, Levy JR, Cheang KI. Comparison of different metabolic syndrome definitions and risks of incident cardiovascular events in the elderly. Metabolism. 2012;61(3):302-9. http://dx.doi.org/10.1016/j.metabol.2011.07.002. PMid:21840552.
20. Paula HA, Ribeiro RC, Rosado LE, Pereira RS, Franceschini SC. Comparação de diferentes critérios de definição para diagnóstico de sÃndrome metabólica em idosas. Arq Bras Cardiol. 2010;95(3):346-53. PMid:20676584.
21. Lee SG, Kim JM, Lee SH, Kim KH, Kim JH, Yi JW, et al. Is the frequency of metabolic syndrome higher in South Korean women with rheumatoid arthritis than in healthy subjects? Korean J Intern Med. 2013;28(2):206-15. http://dx.doi.org/10.3904/kjim.2013.28.2.206. PMid:23526131.
22. Zonana-Nacach A, Santana-Sahagún E, Jiménez-Balderas FJ, Camargo-Coronel A. Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lúpus erythematosus. J Clin Rheumatol. 2008;14(2):74-7. http://dx.doi.org/10.1097/ RHU.0b013e31816b2faa. PMid:18391674.
23. Raterman HG, van Eijk IC, Voskuyl AE, Peters MJ, Dijkmans BA, van Halm VP, et al. The metabolic syndrome is amplified in hypothyroid rheumatoid arthritis patients: a cross-sectional study. Ann Rheum Dis. 2010;69(1):39-42. http://dx.doi.org/10.1136/ard.2008.100776. PMid:19103637.
24. Toms TE, Panoulas VF, John H, Douglas KM, Kitas GD. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther. 2009;11(4):R110. http://dx.doi.org/10.1186/ar2765. PMid:19607680.
25. Dodani S, Henkhaus R, Wick J, Vacek J, Gupta K, Dong L, et al. Metabolic syndrome in South Asian immigrants: more than low HDL requiring aggressive management. Lipids Health Dis. 2011;10(1):45. http://dx.doi.org/10.1186/1476-511X-10-45. PMid:21410987.
26. Salinas MJ, Bertoli AM, Lema L, Saucedo C, Rosa J, Quintana R, et al. Prevalence and correlates of metabolic syndrome in patients with rheumatoid arthritis in Argentina. J Clin Rheumatol. 2013;19(8):439-43. http://dx.doi.org/10.1097/RHU.0000000000000039. PMid:24263146.
27. Karakoc M, Batmaz I, Sariyildiz MA, Tahtasiz M, Cevik R, Tekbas E, et al. The relationship of metabolic syndrome with disease activity and the funcional status in patients with reumatoid arthritis. J Clin Med Res. 2012;4(4):279-285. PMid:22870176.
28. Elkan AC, Håkansson N, Frostegård J, Cederholm T, Hafström I. Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a crosssectional study. Arthritis Res Ther. 2009;11(2):R37. http://dx.doi.org/10.1186/ar2643. PMid:19284557.
29. Dao H-H, Do Q-T, Sakamoto J. Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2010;12(6):R218. http://dx.doi.org/10.1186/ar3203. PMid:21182767.
30. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008;196(2):756-63. http://dx.doi.org/10.1016/j.atherosclerosis.2007.01.004. PMid:17266963.
31. Sahebari M, Goshayeshi L, Mirfeizi Z, Rezaieyazdi Z, Hatef MR, Ghayour-Mobarhan M, et al. Investigation of the association between metabolyc syndrome and disease activity in rheumatoid arthritis. Sci World J. 2011;9(11):1195-205. http://dx.doi.org/10.1100/tsw.2011.111.
32. Karimi M, Mazloomzadeh S, Kafan S, Amirmoghadami H. The frequency of metabolic syndrome in women with rheumatoid arthritis and in controls. Int J Rheum Dis. 2011;14(3):248-54. http://dx.doi.org/10.1111/j.1756-185X.2011.01595.x. PMid:21816020.
33. Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study. Arthritis Res Ther. 2009 jan;11(1):R7. PMid:19144159.
34. Jawaheer D, Messing S, Reed G, Ranganath VK, Kremer JM, Louie JS, et al. Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of north america cohort of rheumatoid arthritis patients. Arthritis Care Res. 2012;64(12):1811-8. http://dx.doi.org/10.1002/acr.21762. PMid:22730408.
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email